Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Neurodevelopmental Outcomes of Preterm Infants Fed High-Dose Docosahexaenoic Acid

Neurodevelopmental Outcomes of Preterm Infants Fed High-Dose Docosahexaenoic Acid ORIGINAL CONTRIBUTION Neurodevelopmental Outcomes of Preterm Infants Fed High-Dose Docosahexaenoic Acid A Randomized Controlled Trial Maria Makrides, BSc, BND, PhD Context Uncertainty exists about the benefit of dietary docosahexaenoic acid (DHA) Robert A. Gibson, BSc, PhD on the neurodevelopment of preterm infants. Andrew J. McPhee, MBBS Objective To determine the effect of meeting the estimated DHA requirement of preterm infants on neurodevelopment at 18 months’ corrected age. Carmel T. Collins, RN, BSSc, PhD Design, Setting, and Participants Randomized, double-blind controlled trial en- Peter G. Davis, MBBS, MD rolling infants born at less than 33 weeks’ gestation from April 2001 to October 2005 Lex W. Doyle, MBBS, MSc, MD at 5 Australian tertiary hospitals, with follow-up to 18 months. Karen Simmer, MBBS, PhD Intervention High-DHA (approximately 1% total fatty acids) enteral feeds com- pared with standard DHA (approximately 0.3% total fatty acids) from day 2 to 4 of Paul B. Colditz, MBBS, PhD life until term corrected age. Scott Morris, MBBS, PhD Main Outcome Measures Bayley Mental Development Index (MDI) at 18 months’ Lisa G. Smithers, BAppSc, PhD corrected age. A priori subgroup analyses were conducted based on randomization strata (sex and birth weight 1250 g vs 1250 g). Kristyn http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/neurodevelopmental-outcomes-of-preterm-infants-fed-high-dose-vIh6MSuU0Q
Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2008.945
pmid
19141765
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Neurodevelopmental Outcomes of Preterm Infants Fed High-Dose Docosahexaenoic Acid A Randomized Controlled Trial Maria Makrides, BSc, BND, PhD Context Uncertainty exists about the benefit of dietary docosahexaenoic acid (DHA) Robert A. Gibson, BSc, PhD on the neurodevelopment of preterm infants. Andrew J. McPhee, MBBS Objective To determine the effect of meeting the estimated DHA requirement of preterm infants on neurodevelopment at 18 months’ corrected age. Carmel T. Collins, RN, BSSc, PhD Design, Setting, and Participants Randomized, double-blind controlled trial en- Peter G. Davis, MBBS, MD rolling infants born at less than 33 weeks’ gestation from April 2001 to October 2005 Lex W. Doyle, MBBS, MSc, MD at 5 Australian tertiary hospitals, with follow-up to 18 months. Karen Simmer, MBBS, PhD Intervention High-DHA (approximately 1% total fatty acids) enteral feeds com- pared with standard DHA (approximately 0.3% total fatty acids) from day 2 to 4 of Paul B. Colditz, MBBS, PhD life until term corrected age. Scott Morris, MBBS, PhD Main Outcome Measures Bayley Mental Development Index (MDI) at 18 months’ Lisa G. Smithers, BAppSc, PhD corrected age. A priori subgroup analyses were conducted based on randomization strata (sex and birth weight 1250 g vs 1250 g). Kristyn

Journal

JAMAAmerican Medical Association

Published: Jan 14, 2009

References